Huoxiang Zhengqi for Covid 19 Market Report 2025

The huoxiang zhengqi for COVID-19 market size has grown rapidly in recent years. It will grow from $1.38 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to increasing demand for traditional Chinese medicine, increasing public awareness of natural remedies, rising cases of gastrointestinal symptoms, increasing demand for immune-boosting products, and a rising number of COVID-19 cases.

The huoxiang zhengqi for COVID-19 market size is expected to see rapid growth in the next few years. It will grow to $2.43 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to the rising popularity of immune health supplements, the rising trend of self-medication for minor health issues, the increasing demand for non-pharmaceutical interventions, the growing accessibility of traditional Chinese medicine products online, and the rising demand for personalized health solutions. Major trends in the forecast period include technology-assisted remote diagnosis, developing new dosage forms, developing synergistic formulations, integration into telehealth platforms, and integration with hospital COVID-19 treatment guidelines.

The forecast of 12.1% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. healthcare providers by inflating prices of Huoxiang Zhengqi herbal preparations imported from China, resulting in delayed alternative COVID-19 treatment options and higher integrative medicine costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising demand for traditional Chinese medicines is expected to drive the growth of the Huoxiang Zhengqi for COVID-19 market. Traditional Chinese medicine (TCM) is an ancient healing system that utilizes herbal remedies, acupuncture, massage, and dietary therapy to balance the body's energy, promote healing, and prevent illness. The increasing demand for TCM is primarily driven by growing interest in natural and holistic health approaches, as consumers seek alternative remedies. Huoxiang Zhengqi for COVID-19 enhances TCM by offering a therapeutic solution that integrates herbal ingredients known for their ability to balance the immune system and alleviate symptoms associated with viral infections. For instance, in January 2025, the National Library of Medicine reported that the export value of traditional Chinese medicine, including medicinal materials and plant extracts, reached \$1.933 billion in 2023. As a result, the growing demand for traditional Chinese medicines is driving the growth of the Huoxiang Zhengqi for COVID-19 market.

The increasing demand for herbal medicine is also expected to propel the growth of the Huoxiang Zhengqi for COVID-19 market. Herbal medicine involves using plants or plant-derived substances for therapeutic purposes to prevent, treat, or manage health conditions. The rising preference for herbal medicine is mainly driven by consumers' interest in natural remedies, as they perceive these alternatives to be safer, with fewer side effects and additional health benefits compared to synthetic drugs. Huoxiang Zhengqi for COVID-19 supports herbal medicine by providing a traditional remedy that boosts immune function, alleviates symptoms, and promotes recovery, showing the role of herbal therapies in managing viral infections. For instance, in September 2024, the HerbalGram reported a 4.4% growth in annual sales of herbal dietary supplements, increasing from \$12.018 billion in 2022 to \$12.551 billion in 2023. Consequently, the growing demand for herbal medicine is fueling the growth of the Huoxiang Zhengqi for COVID-19 market.

The rising incidence of respiratory diseases is expected to drive further growth in the Huoxiang Zhengqi for COVID-19 market. Respiratory diseases are conditions that affect the lungs and respiratory system, often leading to breathing difficulties and impaired lung function. The rise in respiratory diseases is primarily due to increasing air pollution, which exposes individuals to harmful pollutants that irritate the airways and worsen lung health. Huoxiang Zhengqi for COVID-19 aids in treating respiratory diseases by addressing symptoms linked to dampness and digestive imbalances, which are common in respiratory infections. It supports recovery by alleviating nausea, chest congestion, and fatigue, enhancing resilience during mild respiratory illnesses. For instance, in April 2024, the Australian Bureau of Statistics reported a rise in deaths due to acute respiratory infections, with 361 deaths in 2023 compared to 241 in 2022. Thus, the increasing incidence of respiratory diseases is further fueling the growth of the Huoxiang Zhengqi for COVID-19 market.

Major players in the huoxiang zhengqi for COVID-19 market are Yunnan Baiyao Group Co. Ltd., Beijing Tongrentang Co. Ltd., Taiji Group Chongqing Fuling Pharmaceutical Factory Co. Ltd, Zhangzhou Pientzehuang Pharmaceutical Co. Ltd, Tasly Pharmaceutical Group Co. Ltd., Harbin Pharmaceutical Group Co. Ltd., Guizhou Sanli Pharmaceutical Co. Ltd, China Shineway Pharmaceutical Group Limited, Hubei University of Chinese Medicine, Beijing University of Chinese Medicine, Wuhu Zhanghengchun Medicine Co. Ltd.

Asia-Pacific was the largest region in the Huoxiang Zhengqi for COVID-19 market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in huoxiang Zhengqi for COVID-19 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the huoxiang Zhengqi for COVID-19 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The huoxiang Zhengqi for COVID-19 market consists of sales of syrups, powders, injections, essential oils, and nasal sprays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The huoxiang zhengqi for COVID-19 market research report is one of a series of new reports that provides huoxiang zhengqi for COVID-19 market statistics, including the huoxiang zhengqi for COVID-19 industry's global market size, regional shares, competitors with the huoxiang zhengqi for COVID-19 market share, detailed huoxiang zhengqi for COVID-19 market segments, market trends and opportunities, and any further data you may need to thrive in the huoxiang zhengqi for COVID-19 market. This huoxiang zhengqi for COVID-19 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Huoxiang Zhengqi for COVID-19 is a traditional Chinese herbal formula used to treat COVID-19 cases, particularly when gastrointestinal symptoms such as nausea, diarrhea, or fatigue due to dampness are present. The primary aim in this context is to expel dampness, relieve exterior syndromes, and support digestive and immune functions. It is often combined with antiviral and supportive therapies as part of traditional Chinese medicine protocols.

The primary product forms of Huoxiang Zhengqi for COVID-19 include liquid, pills, granules, and other variants. The liquid form of Huoxiang Zhengqi is a traditional herbal remedy designed to alleviate digestive issues such as nausea, vomiting, and bloating by balancing the stomach and spleen. Its typical consumers include health-conscious individuals, those seeking immune system support, alternative medicine supporters, and parents purchasing for their children. It is commonly used for preventive health, managing COVID-19 symptoms, post-recovery health management, as well as for seasonal and illness-related protection. It is suitable for use in hospitals, clinics, home care settings, and other environments, with applications across hospitals, clinics, home care, and additional settings.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.